Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04207710 · ClinicalTrials.gov registry record · Phase 4

Safety of Gebauer's Pain Ease and Gebauer's Ethyl Chloride

A Phase 4 study, sponsored by Henry Ford Health System.

Completed
Registry status
Phase 4
Development phase
72
Enrollment target

NCT04207710 is a Phase 4 study that has completed, run by Henry Ford Health System. The registered enrollment target is 72 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04207710, a Phase 4 study, has completed, sponsored by Henry Ford Health System.

COMPLETED
Registry status
Phase 4
Development phase
72 participants
Enrollment target

Study Summary

This study aims to determine if Gebauer's Pain Ease or Gebauer's Ethyl Chloride topical anesthetic sprays are safe for use as numbing agents prior to placing epidurals and arterial lines, based on whether they introduce increased microbial growth after application to skin. Due to the recent national shortage of lidocaine, we hope to find a suitable alternative to lidocaine for topical analgesia when placing arterial lines and epidurals. Our hypothesis is that the sprays will not affect the sterility of the area. We will compare microbial growth from three subsequent swabs taken from a single area of skin on the wrist and lower back: one with no treatment, the second after treatment with ChloraPrep, and the third after applying one of the numbing sprays. If there is significantly higher growth in the swabs containing the topical anesthetic spray versus the ChloraPrep alone, this will indicate that the sprays introduce microbes to the sites of skin.

Interventions

  • DRUG Gebauer's Pain Ease Top Aerosol Mist Spray
  • DRUG Gebauer's Ethyl Chloride

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2021-01-26
Est. Completion 2022-02-25
Phase Phase 4

Sponsor

Henry Ford Health System

234 total trials

What the Registry Record Tells You About NCT04207710

The ClinicalTrials.gov registry entry for NCT04207710 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Gebauer's Pain Ease Top Aerosol Mist Spray is the first listed.

NCT04207710 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04207710 about?

NCT04207710 is a clinical study titled "Safety of Gebauer's Pain Ease and Gebauer's Ethyl Chloride". This study aims to determine if Gebauer's Pain Ease or Gebauer's Ethyl Chloride topical anesthetic sprays are safe for use as numbing agents prior to placing epidurals and arterial lines, based on whether they introduce increased microbial growth after application to skin. Due to the recent national...

What is the current status of trial NCT04207710?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 72 participants. The study started on 2021-01-26. Estimated completion is 2022-02-25.

What interventions are being tested in trial NCT04207710?

The interventions under investigation include: Gebauer's Pain Ease Top Aerosol Mist Spray (DRUG), Gebauer's Ethyl Chloride (DRUG).

Who is sponsoring clinical trial NCT04207710?

This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.